Unknown

Dataset Information

0

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.


ABSTRACT: BACKGROUND:FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature in four different subtypes. Relevance of CMS for the treatment of mCRC has yet to be defined. PATIENTS AND METHODS:In this exploratory analysis, patients were grouped according to the previously published tumor CRC-CMSs. Objective response rates (ORR) were compared using chi-square test. Overall survival (OS) and progression-free survival (PFS) times were compared using Kaplan-Meier estimation, log-rank tests. Hazard ratios (HR) were estimated according to the Cox proportional hazard method. RESULTS:CMS classification could be determined in 438 out of 514 specimens available from the intent-to-treat (ITT) population (n?=?592). Frequencies for the remaining 438 samples were as follows: CMS1 (14%), CMS2 (37%), CMS3 (15%), CMS4 (34%). For the 315 RAS wild-type tumors, frequencies were as follows: CMS1 (12%), CMS2 (41%), CMS3 (11%), CMS4 (34%). CMS distribution in right- versus (vs) left-sided primary tumors was as follows: CMS1 (27% versus 11%), CMS2 (28% versus 45%), CMS3 (10% versus 12%), CMS4 (35% versus 32%). Independent of the treatment, CMS was a strong prognostic factor for ORR (P?=?0.051), PFS (P?

SUBMITTER: Stintzing S 

PROVIDER: S-EPMC6927316 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.

Stintzing S S   Wirapati P P   Lenz H-J HJ   Neureiter D D   Fischer von Weikersthal L L   Decker T T   Kiani A A   Kaiser F F   Al-Batran S S   Heintges T T   Lerchenmüller C C   Kahl C C   Seipelt G G   Kullmann F F   Moehler M M   Scheithauer W W   Held S S   Modest D P DP   Jung A A   Kirchner T T   Aderka D D   Tejpar S S   Heinemann V V  

Annals of oncology : official journal of the European Society for Medical Oncology 20191101 11


<h4>Background</h4>FIRE-3 compared first-line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wild-type metastatic colorectal cancer (mCRC) patients. The consensus molecular subgroups (CMS) are grouping CRC samples according to their gene-signature in four different subtypes. Relevance of CMS for the treatment of mCRC has yet to be defined.<h4>Patients and methods</h4>In this exploratory analysis, patients were grouped according to the previously published tumor CRC-  ...[more]

Similar Datasets

| S-EPMC3173448 | biostudies-literature
| S-EPMC6342906 | biostudies-literature
| S-EPMC3850951 | biostudies-literature
| S-EPMC6426764 | biostudies-literature
| S-EPMC7851157 | biostudies-literature
| S-EPMC6236022 | biostudies-literature
| S-EPMC3776974 | biostudies-literature
| S-EPMC7505162 | biostudies-literature
| S-EPMC6777349 | biostudies-literature
| S-EPMC9327141 | biostudies-literature